Inov8 AD: Evidence on Matching Reductions in Airborne Pathogens and Patient Infection Rates

Representatives from Inov8 Science Ltd, the wholly owned subsidiary of the AIM listed company Mid-States plc, presented a scientific poster which provides a correlation between the reduction of airborne pathogens and the reduction of infection rates in UK NHS hospitals using the AD during the UK Health Protection 2010 Conference held in Warwick.

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend

(PRWeb UK) November 16, 2010

Representatives from Inov8 Science Ltd, the wholly owned subsidiary of the AIM listed company Mid-States plc, presented a scientific poster which provides a correlation between the reduction of airborne pathogens and the reduction of infection rates in NHS hospitals using the AD during the UK Health Protection 2010 Conference held in Warwick.

The conference was attended by specialists in all fields of health protection and served as a showcase for innovative presentations which demonstrated the latest scientific research and its practical application in three key areas, including preventing and reducing infectious diseases.

Inov8’s Dr Abdel Ezbiri, Chief Scientific Officer and Bob Elen, Business Manager presented quantitative evidence on the correlation between the reduction of bio-burden in hospitals using the Inov8 AD system and the subsequent reduction in cross infection. The evidence was gathered during specific trials conducted in four wards from the Redditch Alexandra Hospital and the Royal Worcester Hospital.

Dr Ezbiri explained, “The findings were positive indeed, as in seven out of eight comparisons with the baseline, the trials showed that there was a significant reduction of environmental bioburden. They also showed that there was a significant reduction in the number of patients infected during the periods when the AD was installed and operational. This demonstrates the strong correlation between bioburden reduction and reduction in patient infection rates.”

Bob Elen continued, “Inov8 has provided new technology in the fight against superbugs, including MRSA, E.coli as well as Norovirus and C.diff. As we gather further data from other sites, we continue to have extremely positive feedback from infection prevention and control staff in other hospitals where the AD system is operational.”

The air disinfection system helps to prevent the airborne spread of a wide range of viruses, bacteria and fungus. The AD provides continuous air disinfection with hydroxyl radicals at levels that mimic atmospheric concentrations which are harmless to humans but extremely effective against bacteria and viruses.

Inov8’s AD system is a winner in the 2009 Smart Solutions Programme for the UK NHS. The system is already in use in clinics and hospitals throughout the world. Inov8 continues to expand internationally through the appointment of specialist distributors.

###


Contact

  • Noreen Cesaero
    Market Accents
    07787 555651
    Email

Attachments